Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijnsma, Kioa Lente, ter Heine, Rob, Moes, Dirk Jan A. R., Langemeijer, Saskia, Schols, Saskia E. M., Volokhina, Elena. B., van den Heuvel, Lambertus P., Wetzels, Jack F. M., van de Kar, Nicole C. A. J., Brüggemann, Roger J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584251/
https://www.ncbi.nlm.nih.gov/pubmed/30758736
http://dx.doi.org/10.1007/s40262-019-00742-8
_version_ 1783428493097304064
author Wijnsma, Kioa Lente
ter Heine, Rob
Moes, Dirk Jan A. R.
Langemeijer, Saskia
Schols, Saskia E. M.
Volokhina, Elena. B.
van den Heuvel, Lambertus P.
Wetzels, Jack F. M.
van de Kar, Nicole C. A. J.
Brüggemann, Roger J.
author_facet Wijnsma, Kioa Lente
ter Heine, Rob
Moes, Dirk Jan A. R.
Langemeijer, Saskia
Schols, Saskia E. M.
Volokhina, Elena. B.
van den Heuvel, Lambertus P.
Wetzels, Jack F. M.
van de Kar, Nicole C. A. J.
Brüggemann, Roger J.
author_sort Wijnsma, Kioa Lente
collection PubMed
description Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.
format Online
Article
Text
id pubmed-6584251
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-65842512019-07-05 Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab Wijnsma, Kioa Lente ter Heine, Rob Moes, Dirk Jan A. R. Langemeijer, Saskia Schols, Saskia E. M. Volokhina, Elena. B. van den Heuvel, Lambertus P. Wetzels, Jack F. M. van de Kar, Nicole C. A. J. Brüggemann, Roger J. Clin Pharmacokinet Review Article Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs. Springer International Publishing 2019-02-13 2019 /pmc/articles/PMC6584251/ /pubmed/30758736 http://dx.doi.org/10.1007/s40262-019-00742-8 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review Article
Wijnsma, Kioa Lente
ter Heine, Rob
Moes, Dirk Jan A. R.
Langemeijer, Saskia
Schols, Saskia E. M.
Volokhina, Elena. B.
van den Heuvel, Lambertus P.
Wetzels, Jack F. M.
van de Kar, Nicole C. A. J.
Brüggemann, Roger J.
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title_full Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title_fullStr Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title_full_unstemmed Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title_short Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
title_sort pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584251/
https://www.ncbi.nlm.nih.gov/pubmed/30758736
http://dx.doi.org/10.1007/s40262-019-00742-8
work_keys_str_mv AT wijnsmakioalente pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT terheinerob pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT moesdirkjanar pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT langemeijersaskia pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT scholssaskiaem pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT volokhinaelenab pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT vandenheuvellambertusp pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT wetzelsjackfm pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT vandekarnicolecaj pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab
AT bruggemannrogerj pharmacologypharmacokineticsandpharmacodynamicsofeculizumabandpossibilitiesforanindividualizedapproachtoeculizumab

Ejemplares similares